Electroceutical® Therapy
Ischemic Heart Disease
Key Facts
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of non-invasive medical devices that deliver proprietary Electroceutical® Therapy to treat inflammatory conditions. Its strategy leverages an initial revenue-generating product, SofPulse®, while advancing a pipeline for severe chronic diseases like ischemic heart disease and traumatic brain injury. Key achievements include FDA clearance for pain and edema, CE Marking, and a pivotal CMS National Coverage Determination for chronic wounds, which significantly enhances reimbursement potential.
View full company profileAbout Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of non-invasive medical devices that deliver proprietary Electroceutical® Therapy to treat inflammatory conditions. Its strategy leverages an initial revenue-generating product, SofPulse®, while advancing a pipeline for severe chronic diseases like ischemic heart disease and traumatic brain injury. Key achievements include FDA clearance for pain and edema, CE Marking, and a pivotal CMS National Coverage Determination for chronic wounds, which significantly enhances reimbursement potential.
View full company profileAbout Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of non-invasive medical devices that deliver proprietary Electroceutical® Therapy to treat inflammatory conditions. Its strategy leverages an initial revenue-generating product, SofPulse®, while advancing a pipeline for severe chronic diseases like ischemic heart disease and traumatic brain injury. Key achievements include FDA clearance for pain and edema, CE Marking, and a pivotal CMS National Coverage Determination for chronic wounds, which significantly enhances reimbursement potential.
View full company profileAbout Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of non-invasive medical devices that deliver proprietary Electroceutical® Therapy to treat inflammatory conditions. Its strategy leverages an initial revenue-generating product, SofPulse®, while advancing a pipeline for severe chronic diseases like ischemic heart disease and traumatic brain injury. Key achievements include FDA clearance for pain and edema, CE Marking, and a pivotal CMS National Coverage Determination for chronic wounds, which significantly enhances reimbursement potential.
View full company profile